Immorna Biotherapeutics, Inc., a China-based clinical stage biotechnology company, announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application for JCXH-211 intravenous (IV), a novel, first-in-class self-replicating mRNA (srRNA) encoding the engineered human interleukin (IL)-12 protein.
The IND approval enables the company to commence a Phase 1/2, multi-centre, open-label, dose escalation and expansion study of JCXH-211, administered intravenously in patients with malignant solid tumours.
The aim of the study is to evaluate the safety and tolerability, and to determine the recommended Phase two dose (RP2D) for JCXH-211 IV along with checkpoint inhibitor (CPI), and to evaluate preliminary efficacy of the combination at the RP2D.
The product is a first-in-class lipid nanoparticle (LNP) encapsulated srRNA, utilising Immorna's proprietary technology, encoding the engineered human IL-12 protein.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study